1. Home
  2. RNP vs DSGN Comparison

RNP vs DSGN Comparison

Compare RNP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers REIT and Preferred and Income Fund Inc.

RNP

Cohen & Steers REIT and Preferred and Income Fund Inc.

HOLD

Current Price

$20.63

Market Cap

980.2M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$15.40

Market Cap

860.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNP
DSGN
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.2M
860.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RNP
DSGN
Price
$20.63
$15.40
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
152.4K
907.2K
Earning Date
01-01-0001
04-28-2026
Dividend Yield
7.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.27
$3.52
52 Week High
$22.99
$17.25

Technical Indicators

Market Signals
Indicator
RNP
DSGN
Relative Strength Index (RSI) 53.13 74.81
Support Level $20.44 $9.78
Resistance Level $20.80 $17.10
Average True Range (ATR) 0.32 0.96
MACD 0.04 0.40
Stochastic Oscillator 85.18 99.43

Price Performance

Historical Comparison
RNP
DSGN

About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.

Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: